11 insiders reported 145 Form 4 transactions for RECURSION PHARMACEUTICALS, INC. (RXRX) over the past 18 months (most recent 2026-08-18). Recent activity: Khan Najat (CEO and President) Sell 80,498 shares, Hallett David (Chief Scientific Officer) Sell 26,657 shares, Taylor Ben R (Chief Financial Officer) Sell 25,018 shares, Borgeson Blake (Director) Sell 30,000 shares, Borgeson Blake (Director) Sell 40,000 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | Khan Najat | CEO and President | Sell | 80,498 | $254,374 |
| 2026-08-18 | Hallett David | Chief Scientific Officer | Sell | 26,657 | $84,236 |
| 2026-08-18 | Taylor Ben R | Chief Financial Officer | Sell | 25,018 | $79,057 |
| 2026-08-06 | Borgeson Blake | Director | Sell | 30,000 | $97,500 |
| 2026-07-09 | Borgeson Blake | Director | Sell | 40,000 | $158,500 |
| 2026-07-02 | Li Dean Y | Director | Buy | 3,747 | $0 |
| 2026-07-02 | Dar Zavain | Director | Buy | 5,109 | $0 |
| 2026-06-22 | Michor Franziska | Director | Buy | 88,424 | $0 |
| 2026-06-22 | Sun Elaine D | Director | Buy | 88,424 | $0 |
| 2026-06-22 | Li Dean Y | Director | Buy | 88,424 | $0 |
| 2026-06-22 | Dar Zavain | Director | Buy | 88,424 | $0 |
| 2026-06-22 | Borgeson Blake | Director | Buy | 88,424 | $0 |
| 2026-06-22 | HERSHBERG ROBERT | Director | Buy | 88,424 | $0 |
| 2026-06-22 | Bumpus Namandje | Director | Buy | 88,424 | $0 |
| 2026-06-22 | Bumpus Namandje | Director | Sell | 3,963 | $12,602 |
| 2026-06-17 | Taylor Ben R | Chief Financial Officer | Sell | 5,396 | $16,997 |
| 2026-06-05 | Gibson Christopher | Director | Buy | 40,000 | $0 |
| 2026-06-05 | Khan Najat | CEO and President | Sell | 23,588 | $84,459 |
| 2026-06-05 | Gibson Christopher | Director | Sell | 40,000 | $144,800 |
| 2026-06-04 | Borgeson Blake | Director | Sell | 30,000 | $110,400 |
| 2026-06-04 | Bumpus Namandje | Director | Sell | 4,386 | $15,526 |
| 2026-05-27 | Gibson Christopher | Director | Buy | 40,000 | $0 |
| 2026-05-27 | Gibson Christopher | Director | Sell | 40,000 | $123,200 |
| 2026-05-19 | Taylor Ben R | Chief Financial Officer | Sell | 25,018 | $76,055 |
| 2026-05-19 | Gibson Christopher | Director | Sell | 22,821 | $69,376 |
Source: SEC Form 4 filings · as of 2026-08-18